Molecular Imaging-Based Dose Painting: A Novel Paradigm for Radiation Therapy Prescription

被引:230
作者
Bentzen, Soren M. [1 ,2 ,3 ,4 ,5 ]
Gregoire, Vincent [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Wisconsin, Dept Human Oncol, Madison, WI 53792 USA
[2] Univ Wisconsin, Dept Med Phys, Madison, WI 53792 USA
[3] Univ Wisconsin, Dept Biostat, Madison, WI 53792 USA
[4] Univ Wisconsin, Dept Med Informat, Madison, WI 53792 USA
[5] Catholic Univ Louvain, St Luc Univ Hosp, Ctr Mol Imaging & Expt Radiotherapy, Dept Radiat Oncol, B-1200 Brussels, Belgium
关键词
POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; TUMOR-CONTROL PROBABILITY; GROWTH-FACTOR RECEPTOR; INTENSITY-MODULATED RADIOTHERAPY; NECK-CANCER; ACCELERATED RADIOTHERAPY; PROSTATE-CANCER; HETEROGENEOUS TUMORS; TARGET VOLUME;
D O I
10.1016/j.semradonc.2010.10.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dose painting is the prescription of a nonuniform radiation dose distribution to the target volume based on functional or molecular images shown to indicate the local risk of relapse. Two prototypical strategies for implementing this novel paradigm in radiation oncology are reviewed: subvolume boosting and dose painting by numbers. Subvolume boosting involves the selection of a "target within the target," defined by image segmentation on the basis of the quantitative information in the image or morphologically, and this is related to image-based target volume selection and delineation. Dose painting by numbers is a voxel-level prescription of dose based on a mathematical transformation of the image intensity of individual pixels. The quantitative use of images to decide both where and how to delivery radiation therapy in an individual case is also called theragnostic imaging. Dose painting targets are imaging surrogates for cellular or microenvironmental phenotypes associated with poor radioresponsiveness. In this review, the focus is on the following positron emission tomography tracers: FDG and choline as surrogates for tumor burden, fluorothymidine as a surrogate for proliferation (or cellular growth fraction) and hypoxia-sensitive tracers, including [18F] fluoromisonidazole, EF3, EF5, and 64Cu-labeled copper(II) diacetyl-di(N4-methylthiosemicarbazone) as surrogates of cellular hypoxia. Research advances supporting the clinicobiological rationale for dose painting are reviewed as are studies of the technical feasibility of optimizing and delivering realistic dose painted radiation therapy plans. Challenges and research priorities in this exciting research field are defined and a possible design for a randomized clinical trial of dose painting is presented. © 2011 Elsevier Inc.
引用
收藏
页码:101 / 110
页数:10
相关论文
共 100 条
  • [1] On biologically conformal boost dose optimization
    Alber, M
    Paulsen, F
    Eschmann, SM
    Machulla, HJ
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2003, 48 (02) : N31 - N35
  • [2] Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models
    Apisarnthanarax, Smith
    Alauddin, Mian M.
    Mourtada, Firas
    Ariga, Hisanori
    Raju, Uma
    Mawlawi, Osama
    Han, Dongmei
    Bornmann, William G.
    Ajani, Jaffer A.
    Milas, Luka
    Gelovani, Juri G.
    Chao, K. S. Clifford
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (15) : 4590 - 4597
  • [3] Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation
    Barwick, Tara
    Bencherif, Badreddine
    Mountz, James M.
    Avril, Norbert
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2009, 30 (12) : 908 - 917
  • [4] The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis
    Begg, AC
    Haustermans, K
    Hart, AAM
    Dische, S
    Saunders, M
    Zackrisson, B
    Gustaffson, H
    Coucke, P
    Paschoud, N
    Hoyer, M
    Overgaard, J
    Antognoni, P
    Richetti, A
    Bourhis, J
    Bartelink, H
    Horiot, JC
    Corvo, R
    Giaretti, W
    Awwad, H
    Shouman, T
    Jouffroy, T
    Maciorowski, Z
    Dobrowsky, W
    Struikmans, H
    Rutgers, D
    Wilson, GD
    [J]. RADIOTHERAPY AND ONCOLOGY, 1999, 50 (01) : 13 - 23
  • [5] The α/β ratio for prostate cancer:: What is it, really?
    Bentzen, SM
    Ritter, MA
    [J]. RADIOTHERAPY AND ONCOLOGY, 2005, 76 (01) : 1 - 3
  • [6] Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial
    Bentzen, SM
    Atasoy, BM
    Daley, FM
    Dische, S
    Richman, PI
    Saunders, MI
    Trott, KR
    Wilson, GD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5560 - 5567
  • [7] Theragnostic imaging for radiation oncology: dose-painting by numbers
    Bentzen, SM
    [J]. LANCET ONCOLOGY, 2005, 6 (02) : 112 - 117
  • [8] Repopulation in radiation oncology: perspectives of clinical research
    Bentzen, SM
    [J]. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2003, 79 (07) : 581 - 585
  • [9] Bentzen Soren M., 2008, P41
  • [10] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    Bonner, JA
    Harari, PM
    Giralt, J
    Azarnia, N
    Shin, DM
    Cohen, RB
    Jones, CU
    Sur, R
    Raben, D
    Jassem, J
    Ove, R
    Kies, MS
    Baselga, J
    Youssoufian, H
    Amellal, N
    Rowinsky, EK
    Ang, KK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) : 567 - 578